<DOC>
	<DOCNO>NCT00920387</DOCNO>
	<brief_summary>This study find whether psychotherapy combine lysergic acid diethylamide ( LSD ) safe helpful people anxious potentially fatal disease . The study measure anxiety quality life people two session either full active placebo dose LSD . They expect LSD-assisted psychotherapy reduce anxiety improve quality life .</brief_summary>
	<brief_title>Lysergic Acid Diethylamide ( LSD ) -Assisted Psychotherapy People With Illness-related Anxiety</brief_title>
	<detailed_description>Diagnosis potentially fatal illness distress provoke anxiety reduces quality life , treatment reduces anxiety face deteriorate health mortality improve quality life people illness . Forty fifty year ago , researcher investigate lysergic acid diethylamide ( LSD ) combination psychotherapy treat anxiety face advanced stage cancer . This psychedelic ( hallucinogenic ) drug produce transformative mystical experience insight help anxiety reduction . This study randomize , active placebo control , double-blind pilot study safety efficacy LSD-assisted psychotherapy way reduce anxiety people potentially fatal illness . This study examine whether two session LSD-assisted psychotherapy schedule two four week apart reduce anxiety improve quality life people experience anxiety result potentially fatal illness . Study subject receive either 200 20 mcg ( microgram ) LSD two day-long psychotherapy session schedule two four week apart . Subjects study 66 % receive full dose 200 mcg LSD , 33 % chance get active placebo dose 20 mcg LSD . Neither researcher subject know whether get 200 20 mcg LSD . Upon participant agreement , psychotherapy session record audio video . The randomized part study last three half month ( 14 week ) . People learn get active placebo dose LSD randomize phase go take part `` open label '' study phase , get full dose LSD two day-long psychotherapy session schedule two four week apart . `` Open label '' mean researcher aware get full dose LSD . Participants receive full dose LSD take part study visit assess symptom anxiety depression quality life 12 month final experimental session .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Lysergic Acid Diethylamide</mesh_term>
	<criteria>Have diagnosis advancedstage potentially fatal illness . As well metastatic cancer may include autoimmune , neurological , infectious rheumatoid disease well . The participant must probability survival six month . The estimated life expectancy relation study must document . The participant make decision participate study inhibition ability decide due primary disease . Meet DSMIV criterion Anxiety Disorder indicate SCID score least 40 part STAI . Have fail respond adequately medication psychotherapy intend reduce anxiety , refuse take anxiolytic medication . May diagnose another affective disorder anxiety disorder , except bipolarI disorder . Are least 18 year age . Are willing commit medication dosing , experimental session , followup session , complete evaluation instrument ( although may withdraw study time without cause ) . Are willing withdraw take psychiatric medication experimental session period . Drugs must discontinue long enough first LSD treatment session avoid possibility drugdrug interaction ( interval least 5 time particular drug 's halflife ) . If ongoing psychotherapy , recruit study may continue see outside therapist , provide sign release investigator communicate directly therapist . Participants change therapist , increase decrease frequency therapy commence new type therapy evaluation session 2 month second LSD treatment session . Participants must agree , one week precede LSD treatment session : . Clinical judgment use determine permissible herbal supplement . b . They initiate new prescription medication ( except prior approval research team ) . c. Clinical judgment use determine permissible nonprescription medication . Participants must willing follow restriction guideline concern consumption food , beverage nicotine night prior LSD session . Women pregnant nursing , child bear potential practicing effective mean birth control . Anyone past present diagnosis primary psychotic disorder . Meeting DSMIV criterion Dissociative Disorder BipolarI Affective Disorder . Meeting DSMIV criterion abuse dependence substance ( caffeine nicotine ) past 60 day . Diagnosed significant somatic problem , clinical judgment investigator pose great potential side effect . No sufficient liver function baseline examination day experimental session . Having evidence CNS affection primary disease ( e.g . brain metastasis ) , show neurocognitive impairment . Weighing less 45 kg . Reasonably judge present serious suicide risk likely require psychiatric hospitalization course study . Unable fully understand potential risk benefit study give informed consent . Requiring ongoing concomitant therapy psychotropic drug ( need , anxiety medication , pain control medication ) unable unwilling comply washout period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>quality life</keyword>
	<keyword>psychotherapy</keyword>
	<keyword>potentially fatal illness</keyword>
	<keyword>lysergic acid diethylamide</keyword>
</DOC>